Imunon (Nasdaq:IMNN) - Hisse Senedi Fiyatı, Haberler ve Analizler

IMNN Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan Imunon, Inc. kanser ve bulaşıcı hastalıkları tedavi etmek için immünoterapiler ve aşılar geliştirmektedir. Daha fazla detay

IMNN temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

1 yıldan az nakit akışı var

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 22% oranında düşmesi öngörülüyor

+ 2 daha fazla risk

Imunon, Inc. Rakipler

Turnstone Biologics

NasdaqGM:TSBX

US$10.9m

iBio

NYSEAM:IBIO

US$22.4m

Aptinyx

OTCPK:APTX

US$6.5m

Senti Biosciences

NasdaqCM:SNTI

US$9.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Imunon
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.81
52 Haftanın En Yüksek Seviyesi	US$3.65
52 Haftanın En Düşük Seviyesi	US$0.48
Beta	2.13
11 Aylık Değişim	-13.91%
3 Aylık Değişim	-35.56%
1 Yıllık Değişim	-7.73%
33 Yıllık Değişim	-92.48%
5 Yıllık Değişim	-95.90%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Hissedar Getirileri

	IMNN	US Biotechs	US Pazar
7D	12.7%	2.4%	2.2%
1Y	-7.7%	16.2%	31.7%

Getiri vs. Endüstri: IMNN geçen yıl % 16.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: IMNN geçen yıl % 31.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement	9.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: IMNN son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: IMNN 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 31% dan 9% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1982	33	Stacy Lindborg	imunon.com

Klinik aşamada bir biyoteknoloji şirketi olan Imunon, Inc. kanser ve bulaşıcı hastalıkları tedavi etmek için immünoterapiler ve aşılar geliştirmektedir. Şirketin lider klinik programı IMNN-001, yumurtalık kanserinin lokalize tedavisi için DNA bazlı bir immünoterapi olup Faz II klinik geliştirme aşamasındadır. Klinik öncesi aşamadaki ürünleri arasında bir COVID-19 güçlendirici aşısı olan IMNN-101; Lassa virüsünün tedavisi için IMNN-102; ve melanomda Trp2 tümör ilişkili antijen kanser aşısı olan IMNN-201 bulunmaktadır.

Imunon, Inc. Temel Bilgiler Özeti

Imunon'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IMNN temel i̇stati̇sti̇kler
Piyasa değeri	US$10.05m
Kazançlar(TTM)	-US$19.45m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.6x

F/K Oranı

IMNN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IMNN gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$1.67m
Brüt Kâr	-US$1.67m
Diğer Giderler	US$17.78m
Kazançlar	-US$19.45m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.34
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

IMNN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IMNN Stoklara Genel Bakış

Risk Analizi

Imunon, Inc. Rakipler

NasdaqGM:TSBX

US$10.9m

NYSEAM:IBIO

US$22.4m

OTCPK:APTX

US$6.5m

NasdaqCM:SNTI

US$9.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Market cap size

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Recent updates

New major risk - Market cap size

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

Price target decreased by 17% to US$10.00

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting